Brief: Karyopharm Therapeutics - Enters Forbearance Agreement And Waiver On Sept 10, 2026 - SEC Filing
11/09/2026 13:06
BRIEF-Karyopharm Therapeutics - Enters Forbearance Agreement And Waiver On Sept 10, 2026 - SEC Filing Sept 11 (Reuters) - Karyopharm Therapeutics Inc. KPTI.O:
KARYOPHARM THERAPEUTICS - ENTERS FORBEARANCE AGREEMENT AND WAIVER ON SEPT 10, 2026 - SEC FILING
KARYOPHARM THERAPEUTICS - DID NOT PAY $15.80 MILLION PRINCIPAL INSTALLMENT DUE SEPT 10, 2026 - SEC FILING
KARYOPHARM THERAPEUTICS - DOES NOT EXPECT TO PAY CASH INTEREST DUE SEPT 30, 2026 - SEC FILING
KARYOPHARM THERAPEUTICS - AGREES TO PAY $20 MILLION IN FEES AS FORBEARANCE CONSIDERATION - SEC FILING
KARYOPHARM THERAPEUTICS - TO PAY FEES IN SHARES OF NEWLY CREATED PREFERRED STOCK - SEC FILING
Source text: [ID:n0001193125-26-388621]
Further company coverage: KPTI.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Karyopharm Therapeutics
See all newsBrief: Karyopharm Therapeutics - Enters Forbearance Agreement And Waiver On Sept 10, 2026 - SEC Filing
Brief: Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Karyopharm Therapeutics Inc. reports results for the quarter ended June 30 - Earnings Summary
Karyopharm Q2 revenue falls as license revenue drops; expects funds to last into September
Karyopharm Therapeutics Inc. expected to post a loss of $1.28 a share - Earnings Preview